{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:22:13Z","timestamp":1781306533207,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09297-5","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:13:44Z","timestamp":1767028424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-5713","authenticated-orcid":false,"given":"T. A.","family":"Lalmahomed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Monninkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"van Rijssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H. E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C. J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R. N.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"9297_CR1","unstructured":"Netherlands Comprehensive Cancer Center. Incidentie prostaatkanker. Available from: https:\/\/iknl.nl\/kankersoorten\/prostaatkanker\/registratie\/incidentie.\u00a0Cited 2023 May 9."},{"key":"9297_CR2","doi-asserted-by":"crossref","unstructured":"Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34716119\/.\u00a0Cited 2025 Jan 7.","DOI":"10.1016\/j.euo.2021.09.006"},{"key":"9297_CR3","doi-asserted-by":"crossref","unstructured":"Culp MBB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31493960\/.\u00a0Cited 2025 Jan 7.","DOI":"10.1016\/j.eururo.2019.08.005"},{"key":"9297_CR4","unstructured":"Sterfte prostaatkanker. Available from: https:\/\/iknl.nl\/kankersoorten\/prostaatkanker\/registratie\/sterfte.\u00a0Cited 2023 Mar 7."},{"key":"9297_CR5","doi-asserted-by":"crossref","unstructured":"Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19917860\/.\u00a0Cited 2025 Jan 7.","DOI":"10.1200\/JCO.2009.24.2180"},{"key":"9297_CR6","unstructured":"Netherlands Comprehensive Cancer Center. Behandeling prostaatkanker. Available from: https:\/\/iknl.nl\/kankersoorten\/prostaatkanker\/registratie\/behandeling-prostaatkanker.\u00a0Cited 2023 May 9."},{"key":"9297_CR7","doi-asserted-by":"crossref","unstructured":"Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol*Biol*Phys. 2019;104(4):778\u201389.","DOI":"10.1016\/j.ijrobp.2019.06.1912"},{"issue":"8","key":"9297_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360.","journal-title":"Lancet Oncol"},{"issue":"7","key":"9297_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787\u201396.","journal-title":"J Clin Oncol"},{"key":"9297_CR10","doi-asserted-by":"crossref","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.71.7397. Cited 2025 Aug 21.","DOI":"10.1200\/JCO.2016.71.7397"},{"key":"9297_CR11","doi-asserted-by":"crossref","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31540791\/. Cited 2023 Mar 17.","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"9297_CR12","doi-asserted-by":"crossref","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2024. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39668103\/. Cited 2025 Feb 3.","DOI":"10.1016\/j.eururo.2024.11.013"},{"key":"9297_CR13","doi-asserted-by":"crossref","unstructured":"Hehakaya C, van der Voort van Zyp JRN, Vanneste BGL, Grutters JPC, Grobbee DE, Verkooijen HM, et al. Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling. Radiother Oncol. 2021;161:74\u201382. Available from: http:\/\/www.thegreenjournal.com\/article\/S0167814021065646\/fulltext. Cited 2023 May 10.","DOI":"10.1016\/j.radonc.2021.05.022"},{"issue":"135","key":"9297_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","volume":"1","author":"Y Alayed","year":"2019","unstructured":"Alayed Y, Cheung P, Chu W, Chung H, Davidson M, Ravi A, et al. Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial. Radiother Oncol. 2019;1(135):86\u201390.","journal-title":"Radiother Oncol"},{"key":"9297_CR15","doi-asserted-by":"crossref","unstructured":"Mohajer J, Dunlop A, Mitchell A, Goodwin E, Nill S, Oelfke U, et al. Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. Clin Transl Radiat Oncol. 2020;26:1\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33241129\/.\u00a0Cited 2023 Mar 17.","DOI":"10.1016\/j.ctro.2020.10.005"},{"key":"9297_CR16","doi-asserted-by":"crossref","unstructured":"Westley RL, Biscombe K, Dunlop A, Mitchell A, Oelfke U, Nill S, et al. Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy. Int J Radiat Oncol Biol Phys. 2024;118(3):682\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37776979\/.\u00a0Cited 2024 May 17.","DOI":"10.1016\/j.ijrobp.2023.09.032"},{"key":"9297_CR17","doi-asserted-by":"crossref","unstructured":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92\u20138.","DOI":"10.1016\/j.radonc.2020.03.015"},{"key":"9297_CR18","doi-asserted-by":"crossref","unstructured":"De Cock L, Draulans C, Pos FJ, Isebaert S, De Roover R, van der Heide UA, et al. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023;185:109713.","DOI":"10.1016\/j.radonc.2023.109713"},{"key":"9297_CR19","doi-asserted-by":"crossref","unstructured":"Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024;201:110568.","DOI":"10.1016\/j.radonc.2024.110568"},{"key":"9297_CR20","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Available from: https:\/\/www.meddra.org\/. Cited 2024 Aug 27."},{"issue":"3","key":"9297_CR21","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","volume":"13","author":"FR Teunissen","year":"2023","unstructured":"Teunissen FR, Willigenburg T, Tree AC, Hall WA, Choi SL, Choudhury A, et al. Magnetic resonance-guided adaptive radiation therapy for prostate cancer: the first results from the MOMENTUM study\u2014an international registry for the evidence-based introduction of magnetic resonance-guided adaptive radiation therapy. Pract Radiat Oncol. 2023;13(3):e261\u20139.","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"9297_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","volume":"4","author":"SU Tetar","year":"2021","unstructured":"Tetar SU, Bruynzeel AME, Oei SS, Senan S, Fraikin T, Slotman BJ, et al. Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on patient-reported outcomes of a prospective phase 2 study. Eur Urol Oncol. 2021;4(4):628\u201334.","journal-title":"Eur Urol Oncol"},{"key":"9297_CR23","doi-asserted-by":"crossref","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31540791\/. Cited 2024 Jun 12.","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"9297_CR24","doi-asserted-by":"crossref","unstructured":"Fayers P, Bottomley A. Quality of life research within the EORTC - the EORTC QLQ-C30. Eur J Cancer. 2002;38(SUPPL. 4):125\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11858978\/. Cited 2024 Aug 27.","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"9297_CR25","doi-asserted-by":"crossref","unstructured":"Chu D, Popovic M, Chow E, Cella D, Beaumont JL, Lam H, et al. Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. J Comp Eff Res. 2014;3(5):523\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25350803\/. Cited 2024 Aug 27.","DOI":"10.2217\/cer.14.41"},{"key":"9297_CR26","doi-asserted-by":"crossref","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28194657\/.\u00a0Cited 2024 Aug 27.","DOI":"10.1007\/s40258-017-0310-5"},{"key":"9297_CR27","unstructured":"The MOMENTUM study: the multiple outcome evaluation of radiation therapy using the MR-Linac study | ClinicalTrials.gov. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04075305?term=MOMENTUM&rank=6. Cited 2024 Sep 24."},{"key":"9297_CR28","doi-asserted-by":"crossref","unstructured":"de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy. Front Oncol. 2020;10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33014774\/. Cited 2024 Sep 24.","DOI":"10.3389\/fonc.2020.01328"},{"key":"9297_CR29","doi-asserted-by":"crossref","unstructured":"Brand DH, Kirby AM, Yarnold JR, Somaiah N. How low can you go? The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2022;34(5):280\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35260319\/. Cited 2024 Aug 27.","DOI":"10.1016\/j.clon.2022.02.009"},{"key":"9297_CR30","doi-asserted-by":"crossref","unstructured":"Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554\u201368. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20603408\/. Cited 2024 Aug 27.","DOI":"10.1259\/bjr\/31372149"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09297-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:13:46Z","timestamp":1767028426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9297"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09297-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the medical ethical review board NedMec, Utrecht, The Netherlands, on 19 January 2024 (reference number 23\u2013249). Patients are asked for informed consent to participate in the study, knowing that they will be randomized between the standard and the experimental arm; for the use of data collected within this study for future research, and to be approached by the study team for future studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Participant information materials and the informed consent form are available from the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"HM Verkooijen receives research funding from Elekta, the European Commission, the Dutch Cancer Foundation and the Dutch Research Council. JRN van der Voort van Zyp receives speaker fees from Elekta and Prevents. The other authors do not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"586"}}